Serpin B-2 (Recombinant)

Recombinant Protein · expressed in HEK293
Citation tracking pending
Recombinant human Serpin B-2 (PAI-2, UniProt P05120), expressed in HEK293 cells. Full 415-residue sequence; suited for uPA inhibition assays, fibrinolysis studies, and antibody validation paired with RP-SerpinB2.
Expression system
HEK293
Cat. #
REC-SerpinB2

In stock

SKU
REC-SerpinB2
$498.00

Target Overview

Serpin B-2 (PAI-2; SERPINB2; UniProt P05120) is a 415-amino-acid serine protease inhibitor of the clade B (ov-serpin) family. Unlike the endothelial cell-derived PAI-1 (SERPINE1), PAI-2 is primarily expressed in monocytes and placental tissue and functions as a physiological inhibitor of urokinase-type plasminogen activator (uPA). Its canonical mechanism involves formation of a stable, covalent acyl-enzyme complex with the active-site serine of uPA, thereby attenuating plasminogen activation and downstream fibrinolysis. PAI-2 is also constitutively cytoplasmic in many cell types, where a non-inhibitory pool has been implicated in keratinocyte differentiation and intracellular scaffolding functions that are independent of protease inhibition. This recombinant is produced in HEK293 cells, providing mammalian post-translational processing appropriate for structural and functional studies of the native inhibitor. HEK293 expression is particularly relevant for PAI-2 because the protein is known to form non-covalently associated dimers and higher-order polymers whose assembly is sensitive to the folding environment; prokaryotic expression often produces inclusion bodies that require refolding. In the laboratory, this recombinant serves multiple purposes: as an active inhibitor standard in chromogenic or fluorogenic uPA activity assays, as a competition reagent in inhibitor IC50 determinations, and as a positive-control antigen in Western blot and ELISA validation experiments. Researchers validating anti-SERPINB2 antibodies can pair this recombinant directly with the matched Triple Point Biologics antibody (RP-SerpinB2) to confirm band identity, optimize loading, and establish signal linearity. Its defined sequence and mammalian glycosylation profile also make it suitable as a reference standard in quantitative proteomic workflows.

Background

Serpin B-2 (PAI-2) was first isolated as a plasminogen activator inhibitor distinct from PAI-1 on the basis of its monocyte origin, cytoplasmic localisation, and preferential inhibition of uPA over tissue-type plasminogen activator (tPA). Its biological role sits at the intersection of fibrinolysis regulation, innate immunity, and epithelial homeostasis — contexts that have driven substantial interest in SERPINB2 as a research target across several disease areas. In the fibrinolysis field, SERPINB2 expression has been studied in the context of chronic inflammatory airway disease. Zhu et al. (2026) reported that epithelial SERPINB2 overexpression in chronic rhinosinusitis with nasal polyps was associated with impaired fibrinolysis, at least in part through concurrent downregulation of tPA, establishing a mechanistic link between local serpin upregulation and extracellular matrix remodelling in mucosal tissue (PMID 42216541). This type of study illustrates how recombinant PAI-2 can serve as a functional standard when assessing the relative contributions of PAI-1, PAI-2, and tPA to net fibrinolytic capacity in complex tissue lysates. SERPINB2 has also appeared in proteomic discovery studies of vascular and haematological conditions. Collado-Cuadrado et al. (2026) identified SERPINB2 among proteins associated with endothelial activation and hemostatic imbalance in a parasitological model of vascular remodelling (PMID 41897903). Similarly, gene expression profiling in sickle cell disease identified SERPINB2 transcript changes in the context of vaso-occlusive episodes, pointing to its potential utility as a transcriptomic marker in haematological research (Bhat et al., 2026; PMID 41797711). Beyond vascular biology, SERPINB2 has been examined in cancer research. Neuro-immune gene signature studies in bladder cancer identified SERPINB2 among a cluster of serpin-family members with prognostic correlates, though the authors noted the distinction between SERPINB2 and the closely related SERPINE2 is important when interpreting these datasets (Nie et al., 2026; PMID 41800135). Gastrointestinal research has similarly flagged SERPINB2 as a potential biomarker candidate in Crohn's disease through integrative machine-learning and colocalization analyses (Chen et al., 2026; PMID 41773807). Across these research contexts, a well-characterised recombinant PAI-2 standard is useful for: confirming antibody specificity by antigen competition, calibrating quantitative immunoassays, and establishing enzyme-inhibitor kinetics (Ki, association rate constants) against commercial or purified uPA preparations. Triple Point Biologics has produced serpin and proteinase inhibitor research reagents since 1994; this HEK293-expressed Serpin B-2 is consistent with that validated reagent portfolio.

Applications

  • Urokinase-type plasminogen activator (uPA) inhibition assay — determination of inhibitory rate constant (k_ass) and stoichiometry of inhibition
  • Fibrinolytic activity assay — recombinant PAI-2 used as a defined inhibitor standard alongside tPA and uPA in chromogenic plasminogen activation cascades
  • Inhibitor IC50 / competition screen — titration of PAI-2 against uPA in fluorogenic substrate (e.g., Boc-Glu-Gly-Arg-AMC) format to benchmark test compounds
  • Antibody validation positive control — paired with matched Triple Point Biologics antibody RP-SerpinB2 for Western blot band identification and ELISA signal calibration
  • Quantitative ELISA standard curve — serial dilution of recombinant PAI-2 for absolute quantification of endogenous SERPINB2 in cell lysates or conditioned media
  • Surface plasmon resonance (SPR) or biolayer interferometry (BLI) — immobilised PAI-2 for binding kinetics of anti-SERPINB2 antibodies or candidate small-molecule ligands
  • Serpin polymerisation / conformational study — mammalian-expressed PAI-2 as a substrate for native PAGE, SEC-MALS, or cryo-EM investigation of dimer and polymer assembly

References

  1. Zhu Y et al. Epithelial SERPINB2 Overexpression Contributes to Impaired Fibrinolysis in Chronic Rhinosinusitis With Nasal Polyps via tPA Downregulation. Front Biosci (Landmark Ed). 2026. doi:10.31083/FBL50406. PMID: 42216541
  2. Collado-Cuadrado M et al. Proteomic Analysis of Endothelial Activation Induced by Adult Angiostrongylus vasorum Homogenate: Insights into Vascular Remodeling and Hemostatic Imbalance. Animals (Basel). 2026. doi:10.3390/ani16060926. PMID: 41897903
  3. Nie Q et al. Neuro-immune-related gene signatures define molecular subtypes and prognostic score in bladder cancer with SERPINE2 as a potential therapeutic target. PeerJ. 2026. doi:10.7717/peerj.20917. PMID: 41800135
  4. Bhat V et al. Gene expression profiling identifies potential biomarkers for vaso-occlusive episodes in sickle cell disease. JCI Insight. 2026. doi:10.1172/jci.insight.193359. PMID: 41797711
  5. Chen L et al. Identification of Novel Biomarkers for Crohn's Disease Through the Integration of Machine Learning, Colocalization, and SMR Analysis. FASEB J. 2026. doi:10.1096/fj.202504792R. PMID: 41773807

Additional Specifications

Storage Buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol
Endotoxin Level <0.1 EU/µg by LAL
Purity (%) >90% by SDS-PAGE
Expression System HEK293
Subcellular Localization Secreted; blood plasma

Frequently Asked Questions

What molecular weight should I expect for recombinant Serpin B-2 on SDS-PAGE and Western blot?

Recombinant Serpin B-2 (PAI-2; P05120) runs at approximately 47–50 kDa under reducing SDS-PAGE conditions, slightly above its calculated molecular weight of ~45 kDa for the 415-amino-acid sequence. The upward shift is typical for this protein and reflects its glycosylation profile, which is preserved in the HEK293 expression system used here. Under non-reducing conditions a minor high-molecular-weight smear can appear due to intermolecular disulfide-linked species. Purity is >95% by SDS-PAGE. If you are running a Western blot positive control alongside RP-SerpinB2 antibody, load this band as your reference.

Does this recombinant Serpin B-2 correspond to the glycosylated or non-glycosylated isoform of PAI-2?

PAI-2 (SERPINB2) is naturally expressed in two forms: a non-glycosylated intracellular form (~47 kDa) and a secreted, N-glycosylated form (~60 kDa). This recombinant is produced in HEK293 cells with a secretion signal, yielding the glycosylated, secreted-equivalent form that migrates at ~47–50 kDa under our expression conditions. Full 60 kDa glycosylation seen in some primary placental sources is not always recapitulated at equivalent density in HEK293; if your assay is sensitive to glycan composition, PNGase F digestion of a test aliquot before use is advisable for confirmation.

What protease does recombinant Serpin B-2 inhibit and what is the preferred substrate for an activity assay?

Serpin B-2 (PAI-2) is a physiological inhibitor of urokinase-type plasminogen activator (uPA; PLAU). In a functional inhibition assay, incubate recombinant PAI-2 with two-chain uPA, then monitor residual uPA amidolytic activity using the chromogenic substrate Spectrozyme UK (H-D-Glu-Gly-Arg-pNA·2HCl) or the equivalent Boc-Glu-Gly-Arg-AMC fluorogenic substrate at 0.2–0.5 mM in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.01% Tween-20. PAI-2 forms a covalent acyl-enzyme complex with uPA's active-site Ser195, providing a clean endpoint for stoichiometric inhibition studies. Tissue-type plasminogen activator (tPA) inhibition is roughly 10-fold weaker and not the recommended primary readout.

What starting concentration of recombinant Serpin B-2 should I use for a uPA inhibition assay and how does IC50 vary with uPA concentration?

Because PAI-2 is a stoichiometric, covalent inhibitor rather than a classical competitive inhibitor, IC50 is not a fixed intrinsic constant — it scales linearly with uPA concentration (a consequence of tight-binding inhibition kinetics). As a practical starting point, use 50–200 nM recombinant PAI-2 paired with 10–50 nM two-chain uPA in assay buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.01% Tween-20, 37 °C). Titrate PAI-2 from 0.1× to 5× the uPA molar concentration to bracket the inhibition curve. For second-order rate constant (k2) determinations, pseudo-first-order conditions with a ≥10-fold molar excess of PAI-2 over uPA are standard.

What buffer conditions are optimal for storing and diluting recombinant Serpin B-2 before assay?

The supplied storage buffer is 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol. Aliquots are stable at −20 °C for at least 12 months; avoid repeated freeze-thaw cycles, as serpins are susceptible to latency conversion (loop insertion without cleavage) upon thermal cycling. For assay dilutions, exchange into or dilute into the same Tris-NaCl buffer minus glycerol, adding 0.01–0.05% Tween-20 or 0.1% BSA as a carrier to prevent surface adsorption at sub-nanomolar concentrations. Do not dilute into phosphate buffers below pH 7.0, as serpin conformation is pH-sensitive in the 6.5–7.0 range.

Can I use recombinant Serpin B-2 as a positive control for Western blot with the RP-SerpinB2 rabbit polyclonal antibody?

Yes — this is the primary intended cross-use case. Recombinant Serpin B-2 (REC-SerpinB2) and the matched rabbit polyclonal antibody (RP-SerpinB2) are developed from the same lab and validated together for Western blot. Load 20–50 ng of recombinant protein per lane alongside your cell lysate lanes; under standard reducing SDS-PAGE you will see a clean ~47–50 kDa band that serves as an unambiguous size and signal reference. The matched antibody page is at /anti-serpin-b2-rabbit-polyclonal-antibody. This pairing is particularly useful when validating antibody lot-to-lot consistency or when establishing detection sensitivity in new cell line lysates.

How much recombinant Serpin B-2 should I load for a Western blot positive control, and what dilution of RP-SerpinB2 antibody should I use?

Load 20–50 ng of REC-SerpinB2 per lane for a positive control band. At this amount, RP-SerpinB2 rabbit polyclonal antibody (SKU: RP-SerpinB2) typically performs well at a primary antibody dilution of 1:1,000–1:2,000 in 5% non-fat milk/TBST with a 1-hour room-temperature or overnight 4 °C incubation. For high-sensitivity detection (e.g., ECL plus or fluorescent secondary), 10–20 ng may be sufficient and will reduce background. Always run the recombinant in a lane separate from the highest-concentration lysate to avoid signal bleed-over distorting band interpretation.

How do I reconstitute or dilute recombinant Serpin B-2 from a frozen stock without losing activity?

Aliquots are supplied ready-to-use in solution (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol) — no lyophilization step is required. Thaw a single-use aliquot on ice (10–15 minutes), briefly spin at 10,000 × g for 30 seconds to collect any condensate, then dilute directly into your assay buffer. Avoid vortexing; serpins can partially unfold under shear. If working at concentrations below 10 nM, add 0.1% BSA or 0.05% Tween-20 to prevent adsorptive loss to tube walls. Discard unused diluted material; do not refreeze working dilutions. Opened stock vials can be held at 4 °C for up to 7 days without significant activity loss.

Validation imagery coming soon

Western blot validation figures for REC-SerpinB2 will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →